Company
Smith & Nephew PLC
LON:SN.
Smith & Nephew develops advanced medical devices for healthcare professionals around the world
147 stories · page 1 of 2
Smith & Nephew says 'on track' to meet full-year revenue forecast
The medical products company left its trading profit margin guidance for the year unchanged at around 17.5%
Smith & Nephew little boosted by rivals' reports of improving hip and knee sales
Johnson & Johnson said sales of hip and knee implants and other surgical devices rose 7.7% in the third quarter
Smith & Nephew's shares slump as profit margins squeezed
Revenue slipped 3.1% to US$1.29bn for the second quarter
Smith & Nephew revenues jump as elective procedure volumes rebound
Revenue growth was 4.1% in established markets compared to 1.6% reported
Smith & Nephew FY operating profits double; CEO to depart
"We finished 2021 with a solid fourth quarter, despite nearly a week less trading than in 2020 and the impact of Omicron," said CEO Roland Diggelmann
Smith & Nephew sees full-year performance at low end of guidance on impact from Delta variant and supply chain issues
Orthopaedics revenue fell 5.9% in the third quarter
Smith & Nephew shares represent a “rare value opportunity”, according to a leading investment bank
The number crunchers at Credit Suisse rate the stock 'outperform'
Smith & Nephew growth drivers underappreciated, says Credit Suisse
The bank's analysts said that investors “underestimate the combined power of recently-acquired growth drivers" and that they expected the medical equipment group’s stock to “reverse its material underperformance over the past 12 months”
Smith & Nephew sees the light at the end of the tunnel
The firm is benefitting from vaccine rollouts and healthcare systems reopening to non-urgent surgery
Smith & Nephew suffers nasty fall
The company said the COVID-19 pandemic continued to have an impact on trading performance as hip and knee replacement operations the world over were delayed
Smith & Nephew sales fall faster as surgeries postponded due to coronavirus
Underlying sales fell around 7% in the fourth quarter, compared to 4.2% in the third and 18.7% in the first half
Smith & Nephew returns to growth in US division but gives no guidance
The US was up 1% on an underlying basis but was offset by a 6% decline in other established markets
Smith & Nephew posts quarterly revenue recovery
Third-quarter revenue only dipped 4% compared to a 29% decline in the previous three months
Smith & Nephew stumbles to loss after pandemic hits surgeries
The interim dividend of 14.4 cents per share is the same as was declared a year ago
Smith & Nephew sales decline eases in June as more elective surgeries begin
Hip and knee reconstruction, sports injuries, and ENT businesses were hit hardest by the impact of the pandemic
Smith & Nephew monthly revenue nearly halves as most markets stop non-emergency surgery
Procedures are starting to return in some countries, including the US, while China has shown improved trading
Smith & Nephew weak as Citigroup downgrades to ‘neutral’ citing impact of coronavirus pandemic
The US investment bank also cut its earnings per share estimates for the FTSE 100-listed firm by 15%-22% and reduced its target price to 1,700p from 2,250p
Smith & Nephew appoints new chief financial officer
Anne-Francoise Nesmes is currently holding the same role at leisure parks operator Merlin Entertainments
Smith & Nephew drops guidance as surgical procedures stop amid pandemic
Underlying revenue growth in the quarter to March is expected to drop 8% on 2019
Analysts mull Smith & Nephew's big coronavirus assumptions
“The near term downside risk…is that either China remains challenged for longer, or COVID-19 spreads more widely,” said analysts at JPMorgan Cazenove
Smith & Nephew's 2019 revenue growth at the top end of the range
The medical devices maker had guided towards revenue growth of 3.5-4.5%; it achieved growth of 4.4%
Smith & Nephew acquires grommet maker Tusker Medical
Tusker Medical has developed Tula System, a technology that allows children to receive the correct treatment for ear infections without undergoing surgery
Smith & Nephew replaces guidance for revenues and profit margins
The target for trading profit margins was trimmed due to dilution from acquisitions, currency headwinds and continued investment in the business
Smith & Nephew replaces CEO again
Chief executive Namal Nawana, who joined in May last year, will leave the artificial hip and knee company at the end of the month
Investments and investor services
Small-Cap Snapshot: Staffing company Insperity spikes on 4Q beat; Avaya plunges on 1Q sales miss
Also in play is a proposed merger between the UK's Smith & Nephew and US-based NuVasive Inc
Smith & Nephew slips on downgrade from JP Morgan Cazenove
Shares in the artificial joints maker performed well last year, but analysts reckon risk-reward is now “more balanced”
Morgan Stanley reckons new Smith & Nephew boss can “reinvigorate” artificial hip maker
“We upgrade to ‘overweight’ on the basis that, following several years of stagnation, new management should help reinvigorate top-line performance”
Smith & Nephew on track to deliver full-year guidance as third-quarter revenue rises thanks to strong demand in US, emerging markets
In a brief trading update, the FTSE 100-listed medical technology group said its third-quarter revenue was US$1.169bn, up 2% on a reported basis and 3% on an underlying basis
FTSE 100 closes lower as sterling gains on BoE rate comments
The bank suggested there could be a faster pace of hikes if the UK gets a smooth Brexit deal
Archive
No change expected from Bank of England on 'Super Thursday' despite Budget optimism
Aside from the BoE interest rate decision, the Day Ahead will also bring updates from the likes of BT Group, Royal Dutch Shell, Smith & Nephew, Shire, Just Eat, and Indivior
Smith & Nephew downgraded to 'hold' by HSBC as it awaits signs of a turnaround
"For Reconstruction (32% of sales) we anticipate an uptick in Knee (+4%) and Hip implants (+1.5%), rebounding from the soft start to the year that was affected by fewer elective surgeries in the US and UK," HSBC said
Investments and investor services
FTSE 100 closes firmly lower as trade fears, bond yields and sterling rise creates perfect storm
The Footsie closed down nearly 92 points at 7,418, while the other major European benchmarks were also lower.
Investments and investor services
DFS Furniture set to release full year results, have investors already heard the worst?
DFS and Electrocomponents are set to be among Thursday's highlights.
Archive
Jack’s store roll-out in focus as Tesco reports first half results
The week ahead includes Tesco interims, full-year earnings from DFS Furniture and Ferguson, an Electrocomponents trading update and the US non-farm payrolls report
UBS downgrades Smith & Nephew on surgical robot market concerns
UBS also sees a potential slowdown in Smith & Nephew's hip and knee market
New Smith & Nephew boss gives bullish assessment of artificial hip maker’s health
Namal Nawana’s upbeat comments came as Smith & Nephew reported a 4% rise in half-year revenue, confirmed its cost-cutting strategy is progressing well and reiterated full-year guidance
FTSE 100 keeps head above water at close: Facebook in focus
The Nasdaq on Wall Street is down over 88 points at the time of writing, at 7,420.
Archive
Blue-chip deluge on Thursday with Royal Dutch Shell, AstraZeneca and Diageo (and more) set to report
Three of the 10 largest London-listed companies (by capitalisation) are updating the market on Thursday. A dozen or more other household names are also expected to report.
Smith & Nephew shares rally slightly despite a Deutsche Bank downgrade after results disappointment
The German bank’s analysts cut their stance on the FTSE 100-listed artificial hips and knees maker to ‘sell’ from ‘hold’ and reduced their target price to 1,200p from 1.315p
Investments and investor services
Gloo Networks, Midatech Pharma and Anglo African Oil & Gas among Thursday’s small cap movers
A look at some of the biggest risers and fallers in London on Thursday.
Smith & Nephew cuts full year revenue guidance after weaker first quarter
Smith & Nephew said quarterly revenues were hit by one fewer trading day than last year, softer market conditions and a poor performance in the advanced wound bioactives business
Investments and investor services
FTSE 100 closes down as Wall Street remains in the red but rebounds from earlier low
Wall Street recovered from earlier lows but still remain in negative territory
Archive
Glencore reports first quarter production in wake of freeze orders served on DRC assets
The day ahead includes quarterly updates from Glencore and Smith & Nephew
Smith & Nephew gets a leg-up as UBS ups its rating to ‘buy’ from ‘neutral’, spotlighting its robotic systems
UBS’s analysts said: “Our 200 surgeon UBS Evidence Lab survey suggests the industry shift towards robotic systems is both rapid and inevitable, allowing Smith & Nephew to take share from those yet to launch a system”
FTSE 100 closes firmly higher despite disappointing service sector stats
The UK bluechip-benchmark closed over 165 points higher at 7,199, while the FTSE 250 added over 311 points at 19,576
Archive
British Airways owner IAG and rival easyJet expected to continue March airline traffic boost
The day ahead includes March traffic from blue chip airlines easyJet PLC and British Airways owner International Airlines Group PLC, plus a trading update from Electrocomponents PLC
Smith & Nephew says former Alere boss, Namal Nawana to join as chief executive from next month
Nawana was most recently chief executive of medical diagnostics company Alere, overseeing its US$5.3bn acquisition by Abbott Laboratories in 2017
Archive
Topps Tiles, IAG, easyJet, Electrocomponents and US jobs in focus after Easter break
The week ahead includes interims from Topps Tiles, traffic statistics from easyJet and IAG, a trading statement from Electrocomponents and the US non-farm payrolls report
Flying Brands lifts off as it confirms advanced talks regarding a North American acquisition
A look at some of the biggest risers and falls on the London market today
Knee implants helped revenues and profits to kick in at Smith & Nephew last year
In the 12 months ended December 31 revenues grew 2% to US$4.77bn, while operating profits jumped 16% to US$934mln
Investments and investor services
FTSE 100 closes firmly lower as strong pound weighs
The FTSE 100 index – which is chock full of dollar earners – closed around 108 points lower at 7,170
Archive
Smith & Nephew, Bellway and Compass to provide Thursday’s City highlights
Smith & Nephew, Bellway Plc and Compass are on the Thursday's agenda.
Archive
Bank of England rate decision eyed, plus numbers from blue chips BP and Glaxo in coming week
After November's hike, another UK rate rise is unlikely this month, although some Bank of England MPC members may vote for a rise after a unanimous vote in December
Smith & Nephew tops blue chip risers after JP Morgan upgrade
The recent tax reforms and weakening of the US dollar add a combined 10% to JPM’s earnings per share forecasts, while the prospects of a new boss, margin expansion and a possible share buyback mean there are plenty of catalysts ahead
Smith & Nephew updates guidance regarding expected US corporate tax rate following recent changes
The FTSE 100 listed group it now expects a corporate tax rate on its 2018 trading results in the range 20% to 21% for the medium term, barring any changes to tax legislation or other one-off items
Smith & Nephew buys Rotation Medical for US$125mln
Smith & Nephew will pay US$125mln for Rotation Medical plus up to a further US$85mln over the next five years, contingent on financial performance
Archive
Proactive news snapshot: Rose Petroleum, LEKOIL, Diversified Gas & Oil …
A glance at some of the day's highlights from the Proactive Investors newswire
Smith & Nephew says full year growth to be at lower end of guidance range
Outgoing Smith & Nephew chief executive Olivier Bohuon said third quarter revenue was in line with its expectations
FTSE 100 closes at new high
The index of blue-chip shares was up 4 points to 7,554 around 3.50pm
Archive
Friday set to be a quiet one in London, US jobs data the only game in town
Informa and Smith & Nephew are the only London-listed companies with any scheduled news due, so all eyes will turn to economic data
Archive
Interest rate decisions in the UK and US could spook investors in Halloween week
Week ahead includes interest rate decisions from the Bank of England and the US Federal Reserve, as well as updates from HSBC, BT, Next, BP, and Royal Dutch Shell